GSK's Hycamtin Approved For Lung Cancer Treatment

Armen Hareyan's picture

Hycamtin is the first FDA approved oral therapy will allow patients to receive treatment for relapsed small cell lung cancer.

GlaxoSmithKline [NYSE: GSK] announced today approval by the U.S. Food and Drug Administration (FDA) for oral Hycamtin

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.